Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celularity (CELU) Common Equity (2020 - 2025)

Celularity has reported Common Equity over the past 6 years, most recently at -$20.1 million for Q3 2025.

  • Quarterly results put Common Equity at -$20.1 million for Q3 2025, down 216.28% from a year ago — trailing twelve months through Sep 2025 was -$20.1 million (down 216.28% YoY), and the annual figure for FY2024 was $8.8 million, down 78.43%.
  • Common Equity for Q3 2025 was -$20.1 million at Celularity, up from -$25.5 million in the prior quarter.
  • Over the last five years, Common Equity for CELU hit a ceiling of $198.9 million in Q4 2022 and a floor of -$648.2 million in Q2 2021.
  • Median Common Equity over the past 5 years was $31.2 million (2024), compared with a mean of -$4.3 million.
  • Biggest five-year swings in Common Equity: soared 123.16% in 2022 and later plummeted 216.28% in 2025.
  • Celularity's Common Equity stood at $99.4 million in 2021, then skyrocketed by 100.07% to $198.9 million in 2022, then plummeted by 79.41% to $41.0 million in 2023, then plummeted by 78.43% to $8.8 million in 2024, then crashed by 327.38% to -$20.1 million in 2025.
  • The last three reported values for Common Equity were -$20.1 million (Q3 2025), -$25.5 million (Q2 2025), and -$5.5 million (Q1 2025) per Business Quant data.